<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="940">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148910</url>
  </required_header>
  <id_info>
    <org_study_id>26272819.3.0000.0068</org_study_id>
    <nct_id>NCT05148910</nct_id>
  </id_info>
  <brief_title>Breast Cancer and Intrauterine Contraception</brief_title>
  <official_title>Satisfaction, Continuity, and Bleeding Patterns in Patients With Breast Cancer Using Copper and Silver Intrauterine Device (IUD) Compared to Copper IUD: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edson Santos Ferreira-Filho</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nilson Roberto de Melo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Isabel Cristina Esposito Sorpreso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>José Maria Soares Júnior</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>José Roberto Filassi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kátia Cândido Carvalho</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter da Silva Pinheiro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present work seeks an alternative to the copper IUD for contraception in breast cancer&#xD;
      patients, evaluating the satisfaction and continuity of the copper and silver IUD, as well as&#xD;
      the quality of life, compared to the copper IUD, especially in the regarding the menstrual&#xD;
      bleeding pattern of these patients and possible mechanisms that justify such differences. A&#xD;
      randomized (1:1) controlled clinical trial is proposed. Women between 18 and 45 years of age,&#xD;
      diagnosed with breast carcinoma through histopathological study, who have had at least one&#xD;
      vaginal sexual intercourse in life and wish to use intrauterine contraception will be&#xD;
      included.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized (1:1) controlled clinical trial is proposed. Women aged 18 to 45 years,&#xD;
      diagnosed with breast carcinoma through histopathological study will be included. The study&#xD;
      will be conducted at the Family Planning Outpatient Clinic of the Division of Gynecology,&#xD;
      Hospital das Clínicas, Faculty of Medicine, University of São Paulo (HC-FMUSP). The primary&#xD;
      source of recruitment of patients will be the Mastology Outpatient Clinic of the São Paulo&#xD;
      Cancer Institute &quot;Octavio Frias de Oliveira&quot; (ICESP). After selecting the patients and&#xD;
      signing the informed consent form (ICF), research participants will receive specific&#xD;
      reproductive counseling, with guidance on all contraceptive methods available and appropriate&#xD;
      for their health condition.&#xD;
&#xD;
      To minimize selection bias, subjects will be randomized to one of two groups: 1) Copper IUD&#xD;
      (TCu380A); or 2) Copper and silver IUD (TCu380Ag), in a proportion 1:1. The randomization&#xD;
      sequence was generated using the website http://www.randomization.com. Information on which&#xD;
      treatment each woman will be assigned will be kept in a sealed, opaque envelope identified&#xD;
      with a number. The envelope will only be opened after the participant has signed the ICF.&#xD;
      Once the allocation is made, it cannot be changed. Only the professional who inserts the&#xD;
      device knows the type of IUD. Patients will not know which type of IUD they will use to&#xD;
      minimize performance bias, i.e., they will be blinded to the nature of the inserted device.&#xD;
      Blinding will not be revealed until the end of the study.&#xD;
&#xD;
      Patients will be evaluated 3, 6 and 12 months after IUD insertion. This follow-up will be&#xD;
      carried out at the Family Planning Clinic of the Gynecology Division at HC-FMUSP. After&#xD;
      informed consent, patients will be asked about their current age, occupation, scholarship,&#xD;
      ethnicity/race, date of cancer diagnosis, age at menarche and first sexual intercourse,&#xD;
      number of lifetime partners, sexual orientation, number of pregnancies, deliveries and&#xD;
      abortions, duration of breastfeeding, age of first and last birth, date of last menstruation,&#xD;
      lifetime use of hormonal and emergency contraception, condom use, pregnancy desire after&#xD;
      cancer treatment, comorbidities, type of surgery (conservative or mastectomy), current use of&#xD;
      SERMS (selective estrogen receptor modulators; tamoxifen or raloxifene), aromatase inhibitors&#xD;
      and anticoagulants, smoking (quantity and duration), alcoholism (frequency and dose),&#xD;
      physical activity (type, time and duration), family history of malignant neoplasms. Tumor&#xD;
      staging (TNM) and the immunohistochemical panel will also be recorded. In addition, the&#xD;
      menstrual bleeding pattern will be questioned (through the recall of the last three months),&#xD;
      including the interval between cycles, number of days of menstruation and number of pads or&#xD;
      tampons used and the occurrence of menstrual cramps and the use of analgesics during the&#xD;
      menstrual period. At inclusion, weight (kg), height (cm), blood pressure (mmHg), waist&#xD;
      circumference (cm) and hip (cm) will be measured. At the time of the gynecological&#xD;
      examination, Pap smear and endocervical swab for Chlamydia trachomatis (PCR) will be&#xD;
      collected. Blood samples will be collected for the following laboratory tests: blood count&#xD;
      and serum levels of FSH, estradiol, iron, ferritin, transferrin, and total iron binding&#xD;
      capacity. Dependent variables will be considered: continuation rates, satisfaction, quality&#xD;
      of life, pregnancy, rates, and reasons for discontinuation, with an emphasis on abnormal&#xD;
      uterine bleeding. The independent variable will be the IUD type. The control variables will&#xD;
      be the aforementioned clinical and sociodemographic parameters.&#xD;
&#xD;
      After being included in the study, the IUD will be inserted by a trained professional, if&#xD;
      there is assurance that the patient is not pregnant. Hysterometry (in centimeters) will be&#xD;
      measured and recorded before insertion of the IUD. After insertion, the pain attributed to&#xD;
      the procedure will be questioned, in a global way, through a visual analogue pain scale. For&#xD;
      greater uniformity, all IUDs will be inserted on an outpatient basis, without local&#xD;
      anesthesia and/or sedation.&#xD;
&#xD;
      After 30 to 90 days of insertion, patients will undergo a physical examination (visualization&#xD;
      of the IUD thread) and transvaginal ultrasound to verify if the IUD is in situ.&#xD;
&#xD;
      Patients will be evaluated 3, 6 and 12 months after IUD insertion. The clinical performance&#xD;
      of the IUDs will be evaluated, including pregnancy, infection, perforation, expulsion,&#xD;
      continuity of use, reasons for discontinuation, satisfaction with the method, menstrual&#xD;
      bleeding pattern (PABC) and laboratory tests (blood count and serum levels of FSH, estradiol,&#xD;
      iron, ferritin, transferrin, and total iron binding capacity). The PABC (pictorial blood loss&#xD;
      assessment chart) tool will be used to collect information about menstrual bleeding.&#xD;
      Increased uterine bleeding will be defined as a PABC score greater than 100 and/or bleeding&#xD;
      duration greater than 7 days and/or by the woman's subjective perception of increased&#xD;
      menstrual flow.&#xD;
&#xD;
      To assess quality of life, the Medical Outcomes Study 36-Item Short-Form Healty Survey&#xD;
      (SF-36) questionnaire will be used. The European Organization for Research and Treatment of&#xD;
      Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) will also be included.&#xD;
&#xD;
      The collected data will be systematized in confidential spreadsheets for statistical analysis&#xD;
      supervised by a qualified statistician. Quantitative description of the data (mean, median,&#xD;
      standard deviation and relative frequency) will be performed and the analyzes will be&#xD;
      performed using appropriate tests for each type of variable: quantitative variables will be&#xD;
      analyzed by t test (parametric) or Mann-Whitney (non-parametric), according to the normality&#xD;
      of the distribution; and categorical variables will be analyzed by chi-square (χ²) or&#xD;
      Fisher's exact test, according to the number of observed events. The normality of data&#xD;
      distribution will be evaluated using the Kolmogorov-Smirnov and Shapiro-Wilk tests. The time&#xD;
      for the occurrence of events will be described in Kaplan-Meier curves and possible&#xD;
      differences will be analyzed using the log-rank test and using proportional hazards models&#xD;
      (Cox regression) using clinical-demographic and laboratory variables. The results will be&#xD;
      reported as Relative Risk (RR), Odds Ratio (OR) and Hazard Ratios (HR), with 95% confidence&#xD;
      intervals (95%CI). Both intention-to-treat and per-protocol analysis will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuity</measure>
    <time_frame>3 months</time_frame>
    <description>Number of women that decide to continue using the method assigned</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Continuity</measure>
    <time_frame>6 months</time_frame>
    <description>Number of women that decide to continue using the method assigned</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Continuity</measure>
    <time_frame>12 months</time_frame>
    <description>Number of women that decide to continue using the method assigned</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects' Satisfaction</measure>
    <time_frame>3 months</time_frame>
    <description>Number of women who are satisfied with the method assigned</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects' Satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>Number of women who are satisfied with the method assigned</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects' Satisfaction</measure>
    <time_frame>12 months</time_frame>
    <description>A likert Scale including the question &quot;Are you satisfied with the IUD?&quot; and the answers: extremely satisfied; very satisfied; a little satisfied; neither satisfied nor dissatisfied; a little dissatisfied; very dissatisfied; extremely dissatisfied</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding pattern</measure>
    <time_frame>3 months</time_frame>
    <description>Number of days of bleeding, punctuation through pictorial assessment blood chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding pattern</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days of bleeding, punctuation through pictorial assessment blood chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding pattern</measure>
    <time_frame>12 months</time_frame>
    <description>Number of days of bleeding, punctuation through pictorial assessment blood chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36)</measure>
    <time_frame>12 months</time_frame>
    <description>Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC QLQ-C30)</measure>
    <time_frame>12 months</time_frame>
    <description>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete blood count</measure>
    <time_frame>Baseline</time_frame>
    <description>Complete blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete blood count</measure>
    <time_frame>6 months</time_frame>
    <description>Complete blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete blood count</measure>
    <time_frame>12 months</time_frame>
    <description>Complete blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iron</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum iron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iron</measure>
    <time_frame>6 months</time_frame>
    <description>Serum iron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum iron</measure>
    <time_frame>12 months</time_frame>
    <description>Serum iron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin level</measure>
    <time_frame>Baseline</time_frame>
    <description>Ferritin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin level</measure>
    <time_frame>6 months</time_frame>
    <description>Ferritin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin level</measure>
    <time_frame>12 months</time_frame>
    <description>Ferritin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin level</measure>
    <time_frame>Baseline</time_frame>
    <description>Transferrin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin level</measure>
    <time_frame>6 months</time_frame>
    <description>Transferrin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin level</measure>
    <time_frame>12 months</time_frame>
    <description>Transferrin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total iron binding capacity</measure>
    <time_frame>Baseline</time_frame>
    <description>Total iron binding capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total iron binding capacity</measure>
    <time_frame>6 months</time_frame>
    <description>Total iron binding capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total iron binding capacity</measure>
    <time_frame>12 months</time_frame>
    <description>Total iron binding capacity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Copper IUD (TCu380A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women receiving an intrauterine device (IUD) containing 380mm² of copper.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Silver and copper IUD (TCu380Ag)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women receiving an intrauterine device (IUD) containing 380mm² of copper with a silver core.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Silver and copper IUD (TCu380Ag)</intervention_name>
    <description>An intrauterine device containing 380mm² of copper with a silver core.</description>
    <arm_group_label>Silver and copper IUD (TCu380Ag)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Copper IUD (TCu380A)</intervention_name>
    <description>An intrauterine device containing 380mm² of copper.</description>
    <arm_group_label>Copper IUD (TCu380A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women diagnosed with breast carcinoma through histopathological study&#xD;
&#xD;
          -  At least one vaginal sexual intercourse in life&#xD;
&#xD;
          -  Wish to use intrauterine contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently pregnant women&#xD;
&#xD;
          -  Postmenopausal women&#xD;
&#xD;
          -  Hysterectomized and/or bilaterally ovariectomized women&#xD;
&#xD;
          -  Abortion less than four weeks&#xD;
&#xD;
          -  Childbirth less than six weeks&#xD;
&#xD;
          -  Known endometrial cavity changes&#xD;
&#xD;
          -  Severe anemia (hemoglobin &lt; 8 g/dL)&#xD;
&#xD;
          -  Severe thrombocytopenia&#xD;
&#xD;
          -  Acute purulent cervicitis&#xD;
&#xD;
          -  Current endometritis&#xD;
&#xD;
          -  Acute pelvic inflammatory disease&#xD;
&#xD;
          -  Genital tuberculosis&#xD;
&#xD;
          -  Genital bleeding of unknown cause&#xD;
&#xD;
          -  Cervical or endometrial cancer&#xD;
&#xD;
          -  Wilson's disease&#xD;
&#xD;
          -  Cognitive or psychiatric disorder that makes adherence to the study protocol&#xD;
             unfeasible&#xD;
&#xD;
          -  Tubal ligation&#xD;
&#xD;
          -  Women who do not agree to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edmund C Baracat, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose M Soares Junior, PhD</last_name>
    <phone>551126617621</phone>
    <email>jsoares415@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edson S Ferreira-Filho, MD</last_name>
      <phone>+55 (11) 2661-6248</phone>
      <email>edson.f@fm.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>José M Soares-Junior, MD, PhD</last_name>
      <phone>+55 (11) 2661-6248</phone>
      <email>jsoares415@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Edson S Ferreira-Filho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edmund C Baracat, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>contraception</keyword>
  <keyword>intrauterine device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data (IPD) might be available to other researchers after publication of all planned results by research team.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

